An active fixation quadripolar left ventricular lead for cardiac resynchronization therapy with reduced postoperative complication rates.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
03 2022
Historique:
received: 05 11 2021
accepted: 24 12 2021
pubmed: 31 12 2021
medline: 17 3 2022
entrez: 30 12 2021
Statut: ppublish

Résumé

The rate of left ventricular (LV) lead displacement after cardiac resynchronization therapy (CRT) remains high despite improvements in lead technology. In 2017, a novel quadripolar lead with active fixation technology became available in the UK. This was a retrospective, observational study analyzing device complications in 476 consecutive patients undergoing successful first-time implantation of a CRT device at a tertiary center from 2017 to 2020. Both active (n = 135) and passive fixation (n = 341) quadripolar leads had similar success rates for implantation (99.3% vs. 98.8%, p = 1.00), although the pacing threshold (0.89 [0.60-1.25] vs. 1.00 [0.70-1.60] V, p = .01) and lead impedance (632 [552-794] vs. 730 [636-862] Ohms, p < .0001) were significantly lower for the active fixation lead. Patients receiving an active fixation lead had a reduced incidence of lead displacement at 6 months (0.74% vs. 4.69%, p = .036). There was no significant difference in the rate of right atrial (RA) and right ventricular (RV) lead displacement between the two groups (RA: 1.48% vs. 1.17%, p = .68; RV: 2.22% vs. 1.76%, p = .72). Reprogramming the LV lead after displacement was unsuccessful in most cases (successful reprogramming: Active fix = 0/1, Passive fix = 1/16) therefore nearly all patients required a repeat procedure. As a result, the rate of intervention within 6 months for lead displacement was significantly lower when patients were implanted with the active fixation lead (0.74% vs. 4.40%, p = .049). The novel active fixation lead in our study has a lower incidence of lead displacement and re-intervention compared to conventional quadripolar leads for CRT.

Sections du résumé

BACKGROUND
The rate of left ventricular (LV) lead displacement after cardiac resynchronization therapy (CRT) remains high despite improvements in lead technology. In 2017, a novel quadripolar lead with active fixation technology became available in the UK.
METHODS
This was a retrospective, observational study analyzing device complications in 476 consecutive patients undergoing successful first-time implantation of a CRT device at a tertiary center from 2017 to 2020.
RESULTS
Both active (n = 135) and passive fixation (n = 341) quadripolar leads had similar success rates for implantation (99.3% vs. 98.8%, p = 1.00), although the pacing threshold (0.89 [0.60-1.25] vs. 1.00 [0.70-1.60] V, p = .01) and lead impedance (632 [552-794] vs. 730 [636-862] Ohms, p < .0001) were significantly lower for the active fixation lead. Patients receiving an active fixation lead had a reduced incidence of lead displacement at 6 months (0.74% vs. 4.69%, p = .036). There was no significant difference in the rate of right atrial (RA) and right ventricular (RV) lead displacement between the two groups (RA: 1.48% vs. 1.17%, p = .68; RV: 2.22% vs. 1.76%, p = .72). Reprogramming the LV lead after displacement was unsuccessful in most cases (successful reprogramming: Active fix = 0/1, Passive fix = 1/16) therefore nearly all patients required a repeat procedure. As a result, the rate of intervention within 6 months for lead displacement was significantly lower when patients were implanted with the active fixation lead (0.74% vs. 4.40%, p = .049).
CONCLUSION
The novel active fixation lead in our study has a lower incidence of lead displacement and re-intervention compared to conventional quadripolar leads for CRT.

Identifiants

pubmed: 34968010
doi: 10.1111/jce.15346
pmc: PMC9304298
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

458-463

Subventions

Organisme : British Heart Foundation
ID : FS/18/50/33807
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/SCRF/20/32005
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/2019/34842
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. Journal of Cardiovascular Electrophysiology Published by Wiley Periodicals LLC.

Références

JACC Clin Electrophysiol. 2017 Feb;3(2):107-116
pubmed: 28280785
J Cardiovasc Electrophysiol. 2013 Apr;24(4):449-56
pubmed: 23339555
JACC Clin Electrophysiol. 2016 Aug;2(4):426-433
pubmed: 29759861
Eur Heart J. 2013 Aug;34(29):2281-329
pubmed: 23801822
Europace. 2016 Feb;18(2):301-3
pubmed: 26467399
J Am Coll Cardiol. 2008 Oct 21;52(17):1402-9
pubmed: 18940531
Heart Rhythm. 2016 Jun;13(6):1253-9
pubmed: 26829114
J Am Coll Cardiol. 2012 Apr 24;59(17):1509-18
pubmed: 22405632
Eur Heart J. 2019 Sep 14;40(35):2979-2987
pubmed: 30859220
Circulation. 2011 Jan 4;123(1):70-8
pubmed: 21173353
Europace. 2016 Aug;18(8):1235-40
pubmed: 26443447
J Cardiovasc Electrophysiol. 2022 Mar;33(3):458-463
pubmed: 34968010
Pacing Clin Electrophysiol. 2012 Jun;35(6):641-7
pubmed: 22432739
J Cardiovasc Electrophysiol. 2015 May;26(5):540-6
pubmed: 25631303
JACC Clin Electrophysiol. 2019 Sep;5(9):1028-1035
pubmed: 31537331
Pacing Clin Electrophysiol. 2017 Nov;40(11):1291-1297
pubmed: 28940232
Europace. 2014 Apr;16(4):533-40
pubmed: 24072448
J Cardiovasc Electrophysiol. 2020 May;31(5):1147-1154
pubmed: 32162757
Eur Heart J. 2011 Oct;32(20):2516-24
pubmed: 21875862
Anat Rec (Hoboken). 2009 Jan;292(1):23-8
pubmed: 18951506
Indian Heart J. 2015 Dec;67 Suppl 3:S97-9
pubmed: 26995447
Heart Rhythm. 2014 Jul;11(7):1150-5
pubmed: 24801899
N Engl J Med. 2005 Apr 14;352(15):1539-49
pubmed: 15753115
N Engl J Med. 2002 Jun 13;346(24):1845-53
pubmed: 12063368
Europace. 2007 Jul;9(7):516-22
pubmed: 17540662
JACC Clin Electrophysiol. 2016 Feb;2(1):69-77
pubmed: 29766856
Circ Heart Fail. 2013 May;6(3):427-34
pubmed: 23476053
J Am Coll Cardiol. 2017 Sep 5;70(10):1216-1227
pubmed: 28859784

Auteurs

Calum Robertson (C)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Department of Physiology Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, University of Oxford, Oxford, UK.

Owen Duffey (O)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Department of Physiology Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, University of Oxford, Oxford, UK.

Pok-Tin Tang (PT)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Natalie Fairhurst (N)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Cristiana Monteiro (C)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Peregrine Green (P)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Department of Physiology Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, University of Oxford, Oxford, UK.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Joanna Grogono (J)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Mark Davies (M)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Andrew Lewis (A)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Rohan Wijesurendra (R)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Julian Ormerod (J)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

James Gamble (J)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Matthew Ginks (M)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Kim Rajappan (K)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Yaver Bashir (Y)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Tim R Betts (TR)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Neil Herring (N)

Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Department of Physiology Anatomy and Genetics, Burdon Sanderson Cardiac Science Centre, University of Oxford, Oxford, UK.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH